Adenoid cystic carcinoma of the breast is a rare type of breast cancer that forms in glandular tissue and is generally slow-growing. It accounts for only a small share of breast cancer diagnoses, and its cells have a distinctive pattern under the microscope that pathologists recognise. Although it often tests negative for hormone receptors and HER2, it usually behaves less aggressively than many other breast cancers with that receptor pattern, and surgery is the mainstay of how it is treated.
Key Takeaways
- Adenoid cystic carcinoma (ACC) is a rare breast cancer, better known as a cancer of the salivary glands but occasionally found in the breast.
- It is generally slow-growing, and it spreads to the lymph nodes less often than many other breast cancers.
- It commonly tests negative for estrogen receptors, progesterone receptors, and HER2 — yet its behaviour is usually quite different from other “triple negative” cancers.
- Diagnosis rests on the biopsy sample, where the cells show a characteristic pattern of small clusters and tiny tube-like spaces.
- Surgery to remove the tumor is the central treatment; whether radiation or other treatment is added is an individual decision.
- Because it is rare, reliable figures are limited — current figures are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov).
What Adenoid Cystic Carcinoma Is
Every breast cancer is named for the kind of cell it starts in and how it looks under the microscope. Adenoid cystic carcinoma begins in glandular tissue — the tissue that makes fluids. Cancers with this name are much more often found in the salivary glands of the head and neck; the breast version is uncommon, which is why many people diagnosed with it have never heard the name before.
Our pillar guide, Types of Breast Cancer Compared, places rare types like this one alongside the common ones, so you can see where it sits in the overall picture. Like its better-known relative metaplastic breast cancer, it is a reminder that “breast cancer” is a family of diseases, not a single one — and that the exact type on your pathology report shapes everything that follows.
How It Differs From More Common Types
Three features tend to set adenoid cystic carcinoma of the breast apart. First, its growth pattern: the cells form a mix of small solid clusters and tiny round spaces, a pattern the pathologist can recognise. Second, its pace: it typically grows slowly, often over a long period. Third, its receptor pattern: in most cases the cancer does not carry estrogen or progesterone receptors and does not over-produce HER2, so on paper it falls into the “triple negative” group — but its usual behaviour, slow growth and a lower tendency to involve lymph nodes, is quite different from the typical triple negative cancer described in our explainer on triple negative breast cancer.
| Feature | Adenoid cystic carcinoma | Most common types (such as invasive ductal carcinoma) |
|---|---|---|
| How often it occurs | Rare — a small share of all breast cancers | Makes up the large majority of diagnoses |
| Typical pace | Generally slow-growing | Varies widely by type and grade |
| Receptor pattern | Usually negative for ER, PR, and HER2 | Often hormone receptor positive; varies |
| Lymph node involvement | Less common than in many other types | Depends on size and type |
| Main treatment approach | Surgery is central; other treatment is individual | Usually a combination shaped by receptors and stage |
Other rare types share some of this “uncommon and slower” character. Our guides to tubular breast cancer and medullary breast cancer describe two of them, and comparing the descriptions can help you understand why your team focuses on the exact wording of your report rather than on breast cancer in general.
How It Is Found and Diagnosed
Adenoid cystic carcinoma is often found the way many breast cancers are: a lump noticed by hand, or an area picked up on a mammogram and followed up. Because it can grow slowly, the lump may have been present for some time before it is checked. As with any breast change, the finding only receives a name after a biopsy — a small sample of tissue examined under the microscope.
The biopsy is where the diagnosis is truly made. The pathologist looks for the characteristic mixture of cell patterns, and receptor tests are run on the sample. Our guide to understanding your breast cancer pathology report walks through each of these elements in plain language. Because this type is rare, your team may arrange for the slides to be reviewed by a pathologist with particular experience in unusual breast cancers — a second look is a normal part of care for rare diagnoses, not a sign that something has gone wrong. Staging scans or lymph node checks, if recommended, follow the same general pattern as for other breast cancers, and your team will explain which ones apply to you.
How Treatment Is Generally Planned
Surgery to remove the tumor is the central treatment for adenoid cystic carcinoma of the breast. Depending on the tumor’s size and position, that may mean breast-conserving surgery (removing the tumor with a margin of healthy tissue) or mastectomy (removing the whole breast) — our comparison of lumpectomy and mastectomy explains how that decision is generally weighed. Because spread to the lymph nodes is less common with this type, how the nodes are assessed is also an individual discussion with your surgeon.
Radiation therapy after surgery is considered in some cases, particularly after breast-conserving surgery, and your team will talk through whether it fits your situation. Whole-body (systemic) treatments such as chemotherapy play a less central role for most people with this type, because the cancer is usually slow-growing and its receptor pattern limits some of the other drug categories — but this, too, is individual, and it depends on the full picture on your report. No general article can say which combination is right for you: individual cases differ, and your own care team’s reading of your results is what governs your plan.
The Outlook, in General Terms
In general terms, adenoid cystic carcinoma of the breast is regarded as one of the slower-growing, less aggressive types, and many people do well after surgery. Two honest qualifications belong alongside that reassurance. First, “slow-growing” is not the same as harmless — it is still a cancer, it is treated as one, and follow-up matters. Second, this type is known for the possibility of coming back many years later in a small number of cases, which is one reason long-term follow-up is usually part of the plan even when everything has gone well.
Because the condition is rare, firm statistics are hard to come by and easy to misread — a small number of cases produces shaky figures. Where current figures exist, they are published by the American Cancer Society at cancer.org and the National Cancer Institute at cancer.gov. Treat any number you find elsewhere with caution, and ask your own team what the general picture means in the light of your report.
Questions to Ask Your Doctor
- Has my biopsy been reviewed by a pathologist experienced in rare breast cancer types?
- What were my receptor results, and how do they affect my plan?
- Am I a candidate for breast-conserving surgery, or is mastectomy recommended — and why?
- How will my lymph nodes be assessed, given that this type spreads there less often?
- Is radiation therapy recommended in my case? Is any drug treatment being considered?
- What will follow-up look like, and for how long, given that this type can occasionally return late?
Frequently Asked Questions
Is adenoid cystic carcinoma the same cancer people get in the salivary glands?
It shares a name and a microscopic pattern with the salivary gland cancer, and it is much more common there than in the breast. In the breast it tends to behave more gently than the salivary version is known for. Your breast care team will plan treatment based on where your cancer is and what your own report shows.
If it is triple negative, does that mean it is aggressive?
Not necessarily. “Triple negative” only describes the receptor results — it says nothing by itself about pace. Adenoid cystic carcinoma usually tests triple negative yet is generally slow-growing, which is why doctors treat the named type and the full report, not the label alone.
Why is chemotherapy not usually the main treatment?
For most people with this type, the cancer is contained, slow-growing, and removed by surgery, and its receptor pattern means some drug categories used for other breast cancers do not apply. Whether any drug treatment adds benefit in an individual case is a judgement for your team based on your full results.
Can it come back after treatment?
Any breast cancer can return, and this type is noted for occasionally returning after a long interval. That is a reason for steady long-term follow-up rather than alarm — most people remain well. Report any new lump or change to your team whenever it appears.
Where can I find trustworthy information about such a rare type?
Start with the National Cancer Institute at cancer.gov and the American Cancer Society at cancer.org, and bring what you read to your appointments. Rare types attract outdated and anecdotal material online, so checking the source — and checking with your team — matters more than usual.
Related Articles
- Types of Breast Cancer Compared
- Metaplastic Breast Cancer Explained
- Tubular Breast Cancer Explained
- Medullary Breast Cancer Explained
- Understanding Your Breast Cancer Pathology Report
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.